Chemistry-Assisted Proteomic Profiling of O-GlcNAcylation

Qiang Zhu and Wen Yi*

Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

The modification on proteins with O-linked N-acetyl-β-D-glucosamine (O-GlcNAcylation) is essential for normal cell physiology. Dysregulation of O-GlcNAcylation leads to many human diseases, such as cancer, diabetes and neurodegenerative diseases. Recently, the functional role of O-GlcNAcylation in different physiological states has been elucidated due to the booming detection technologies. Chemical approaches for the enrichment of O-GlcNAcylated proteins combined with mass spectrometry-based proteomics enable the profiling of protein O-GlcNAcylation in a system-wide level. In this review, we summarize recent progresses on the enrichment and proteomic profiling of protein O-GlcNAcylation.

Keywords: O-GlcNAcylation, enrichment strategies, mass spectrometry, quantitative proteomics, chemical tools

INTRODUCTION

O-GlcNAcylation is a prevalent form of posttranslational modifications on the hydroxyl group of serine and/or threonine residues (Torres and Hart, 1984). Starting from fructose-6-phosphate, a glycolytic intermediate, a series of enzymatic reactions (collectively termed the hexosamine biosynthetic pathway) generate Uridine-Diphosphate N-acetylglucosamine (UDP-GlcNAc), the sugar donor for protein O-GlcNAcylation (Figure 1). UDP-GlcNAc can also be generated from the exogenous GlcNAc through the salvage pathway (Bond and Hanover, 2015), and by the enzymatic conversion of UDP-GalNAc by UDP-galactose-4′-epimerase (GALE) (Boyce et al., 2011). Despite the occurrence of O-GlcNAcylation on numerous proteins, only two enzymes are responsible for the recycling of this modification in cells. O-GlcNAc transferase (OGT) catalyzes the addition of O-GlcNAc onto diverse protein substrates, while O-GlcNAc hydrolase (OGA) catalyzes the removal of this modification (Haltiwanger et al., 1990; Lubas et al., 1997). Notably, O-GlcNAcylation is reversible and highly dynamic in response to different cellular stimuli to regulate the structure and function of various intracellular proteins (Gao et al., 2001; Jang et al., 2012; Li and Yi, 2014; Ong et al., 2018). Besides, O-GlcNAcylation can interact with other posttranslational modifications including phosphorylation, acetylation and ubiquitination (Vercoutter-Edouart et al., 2015). These features make O-GlcNAcylation a regulator of various important and basic biological processes such as transcription, stem cell differentiation, signal transduction, cell cycle progression, and metabolic reprogramming (Hart et al., 2011; Bond and Hanover, 2015). For example, recent studies revealed that O-GlcNAcylation of Notch1 elevated its stability by abolishing the binding of E3 ubiquitin ligase Itch, thus maintaining the self-renewal of adult neural stem cells (Chen et al., 2021). Tan et al. found that O-GlcNAcylation of serine/arginine-rich protein kinase 2 (SRPK2) promoted de novo lipogenesis by regulating pre-mRNA splicing (Tan et al., 2021). Duan et al. revealed O-GlcNAcylation of RACK1 on serine 122 promoted its protein stability, ribosome binding and interaction with PKCβII to modulate hepatocellular carcinoma (HCC) tumorigenesis (Duan et al., 2018). Consequently, dysregulation of O-GlcNAc cycling has...
been implicated in the pathology of various diseases, including but not limited to, diabetes, cancer, cardiovascular diseases, and neuronal disorders (Slawson and Hart, 2011; Vaidyanathan and Wells, 2014; Yuzwa and Vocadlo, 2014). However, the specific molecular mechanisms by which O-GlcNAcylation contributes to the development and progression of these diseases remain to be elucidated.

Elucidating the function of O-GlcNAcylation in both physiological and pathological processes requires reliable and powerful detection tools to visualize and quantify the dynamics of O-GlcNAcylation. However, it is challenging to detect O-GlcNAcylated proteins by conventional techniques due to the regulatory nature of the modification (e.g., low abundance and highly dynamic) and the unique chemical characteristics (e.g., low immunogenicity and chemically/enzymatically labile) (Thompson et al., 2018). These features have called for the development of effective approaches to enrich and quantify this modification. In this review, we aim to provide a concise summary of recent advances to use chemistry-assisted proteomic methods to profile protein O-GlcNAcylation in a system-wise level.

ENRICHMENT STRATEGIES FOR PROTEIN O-GLCNACYLATION

Antibodies and Lectins

Unlike phosphorylation and other PTMs for which site-specific antibodies are available, effective and specific antibodies for O-GlcNAc are difficult to develop due to the low immunogenicity of the neutral O-GlcNAc sugar (Monsigny et al., 1979). The commonly used O-GlcNAc antibodies are two pan-antibodies (CTD110.6 and RL2), raised against glycopeptides derived from the C-terminal domain of RNA polymerase II, and rat liver nuclear envelopes, respectively (Snow et al., 1987; Comer et al., 2001). In addition, a few mouse monoclonal antibodies were developed, including HGAC85 (Turner et al., 1990), 10D8 (Yoshida et al., 1989), 18B10.7C (#3), 9D1. E4 (#10), and 1F5. D6 (#14) (Teo et al., 2010). These pan-antibodies were produced to yield the broad possible coverage of the modification. Although these antibodies can be employed for the detection of O-GlcNAcylated proteins, they exhibit different substrate recognition specificity. For example, CTD110.6, 18B10.7C (#3), and 9D1. E4 (#10) are more inclined to recognize O-GlcNAc on the cell surface glycoproteins, and CTD110.6 shows cross-reactivity toward GlcNAc-containing N-glycans. RL2 also has a preference toward specific peptide sequences (Tashima and Stanley, 2014). In addition to the antibodies, specific lectins were also used in studies to detect O-GlcNAc. The lectin WGA (Wheat Germ Agglutinin) was first applied to detect and enrich O-GlcNAcylated proteins. But this plant lectin can recognize all terminal GlcNAc sugars as well as sialic acids (Monsigny et al., 1979; Snow et al., 1987). To increase the specificity, the succinyl WGA (sWGA) was developed, in which the recognition of sialic acid was inhibited via succinylation of WGA into the sialic acid.
Metabolic Labeling of O-GlcNAcylated Proteins

Metabolic chemical reporters (MCRs) of glycosylation are unnatural monosaccharide analogs that contain bioorthogonal functionalities such as an alkyne or azide (Grammel and Hang, 2013; Chuh and Pratt, 2015; Chuh et al., 2016). Metabolic incorporation of these MCRs followed by bioorthogonal reactions such as the copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) has been extensively used to label complex glycans containing sialic acids, fucose, GalNAc, or GlcNAc (Figure 2A) (Prescher and Bertozzi, 2005; Best, 2009).

In the detection of O-GlcNAcylation, a few specific MCRs were developed (Figure 2B). The first O-GlcNAc-targeted MCR 1,3,5,6-tetra-O-acetyl-N-azidoacetyl-glucosamine (Ac4GlcNAz) has been employed for the visualization and proteomic profiling of O-GlcNAcylated proteins (Vocadlo et al., 2003). The acetyl groups act as protecting groups to enhance the permeability of GlcNAz into the cell. After deacetylation by cellular esterases, Ac4GlcNAz could be metabolically converted to UDP-GlcNAz which was then transferred to proteins by OGT (Zaro et al., 2011). Using this MCR, Hahne et al. identified about 1,500 O-GlcNAc proteins in cells. Coupled with β-elimination reaction, they mapped 185 O-GlcNAc modification sites on 80 proteins (Hahne et al., 2013). However, GlcNAz showed low selectivity since it could be incorporated into N-glycans (Cieniewski-Bernard et al., 2014). Subsequently, 1,3,5,6-tetra-O-acetyl-N-azidoacetyl-galactosamine (Ac4GalNAz, 2) was used to label O-GlcNAcylated proteins (Boyce et al., 2011). However, further studies revealed that GlcNAz and GalNAz could interconvert to each other in cells, causing the labeling reaction unable to distinguish O-GlcNAc from mucin-type O-linked glycans (Chuh et al., 2014; Qin et al., 2020). To solve this problem, Zaro et al. (2011) employed alkyneacetyl-GlcNAc analogue (GlcNAlk, 3) and alkyneacetyl-GalNAc analogue (GalNAlk, 4) to label O-GlcNAcylated proteins. They found that GlcNAlk could not metabolically convert to GalNAlk, thus it would not label mucin-type O-linked glycans. GalNAlk showed a lower labeling efficiency.
since it was hard to metabolically convert to GlcNAc in cells. Unfortunately, GlcNAc was also incorporated into N-linked glycans, compromising the labeling specificity (Zaro et al., 2011). Chuh et al. (2014) circumvented this limitation by using 1,3,5-tri-O-acetyl-6-azido-6-deoxy-N-acetyl-glucosamine (Ac34dGlcNAz, 5) (Chuh et al., 2014). Unlike the other MCRs mentioned above, 6AzGlcNAc could be directly phosphorylated at the 1-hydroxyl to bypass the canonical GlcNac salvage pathway, which endowed it with a higher degree of selectivity for O-GlcNAcylated proteins (Chuh et al., 2014). However, 6AzGlcNAc showed a lower conversion efficiency to UDP-GlcNAc as compared to GlcNAz, emphasizing the potential balance between labeling efficiency and selectivity. Notably, O-GlcNAcylation is a dynamic process, in which the endogenous OGA can rapidly remove metabolic labels with azide group using β-1,4-galactosyltransferase GaT (Y289L). The biotin with the alkyne group is added to O-GlcNAcylated proteins by copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) chemistry. Following labeling with biotin, O-GlcNAcylated proteins can be captured using streptavidin resin and then simultaneously proteins are digested and analyzed by LC-MS/MS.

FIGURE 3 | Schematic of chemoenzymatic labeling strategy for enrichment and detection of O-GlcNAc proteins. O-GlcNAcylated proteins in cell lysates are labeled with azide group using β-1,4-galactosyltransferase GaT (Y289L). The biotin with the alkyne group is added to O-GlcNAcylated proteins by copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) chemistry. Following labeling with biotin, O-GlcNAcylated proteins can be captured using streptavidin resin and then simultaneously proteins are digested and analyzed by LC-MS/MS.

Chemoenzymatic Labeling of O-GlcNAc Proteins

As a complementary approach to the metabolic labeling, a chemoenzymatic labeling strategy has also been widely used in the capture and profiling of O-GlcNAcylated proteins (Figure 3). The Hart lab first developed a radioassay using a radiolabeled UDP-Gal and the enzyme β-1, 4-galactosyltransferase 1 (GalT1), which specifically transfers Gal to terminal GlcNAc moieties (Hayes et al., 1995; Torres and Hart, 1984). To extend the application of this method, a GalT1 mutant (Y289L) was generated to expand the substrate binding pocket, which allowed for the transfer of UDP-Gal analogues appended with chemical tags including azide, followed by bioorthogonal reactions, O-GlcNAc-modified proteins were biotinylated and subsequently were captured with avidin beads, eluted with free biotin, and sequenced by ETD mass spectrometry. (Figure 3) (Khidekel et al., 2003; Clark et al., 2008). Using this chemoenzymatic labeling strategy, the Hsieh-Wilson group carried out the first glycoproteomic study of O-GlcNAcylated proteins in the rat brain, in which some O-GlcNAc sites on 25 O-GlcNAcylated proteins were mapped (Khidekel et al., 2004). The bulky biotin group compromised the glycopeptide recovery efficiency. In the follow-up studies, a few cleavable enrichment probes were employed to improve the recovery of enriched glycopeptides and increase the rate of true assignment. The Hart group used a photocleavable biotin-alkyne probe to capture GalNAz-tagged O-GlcNAcylated peptides. When exposed to UV light (365 nm), O-GlcNAcylated peptides were released from the avidin chromatography column, followed by protein identification and site mapping by mass spectrometry.
TABLE 1 | The comparison of different detection methods for O-GlcNAcylation.

| Detection methods | Specificity | Sensitivity | Applications | References |
|-------------------|-------------|-------------|--------------|------------|
| Lectin            | Low         | Low         | Western blot, proteomics | Vosseller et al. (2008), Chalkley et al. (2009) |
| Antibody          | Moderate    | Moderate    | Western blot, proteomics | Snow et al. (1987), Teo et al. (2010), Cornier et al. (2001) |
| Metabolic labeling| Moderate    | High        | Western blot, proteomics, live cell imaging, flow cytometry, in-gel fluorescence | Tan et al. (2018), Zaro et al. (2017), Qin W. et al. (2018), Li et al. (2016), Clark et al. (2006) |
| Chemoenzymatic labeling | High       | High        | Western blot, proteomics, in-gel fluorescence, histology, in vivo imaging | Rouhanifard et al. (2014), Aguilar et al. (2017), Li et al. (2019), Clark et al. (2008) |

(Alfaro et al., 2012). Alfaro et al. used a photocleavable biotin probe to enrich and identify 274 O-GlcNAcylated proteins in mouse cerebral tissues (Alfaro et al., 2012). Tsumoto et al. used a novel alkyne probe containing thiol-alkyne to capture O-GlcNAcylated peptides. Glycopeptides were released by the reversible disulfide formation with a thiol-reactive resin (Tsumoto et al., 2015). Griffin et al. developed a probe that would be positively charged when it was cleaved to facilitate ETD-MS detection. An alkyne-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde)-biotin linker was used to label O-GlcNAcylated proteins. The Dde moiety can be quantitatively removed by hydrazine and showed higher labeling efficiency than PC-biotin-alkyne (Griffin et al., 2016). On the other hand, 3-ethynylbenzaldehyde probe was used to react with GalNAz via the copper-catalyzed Huisgen 1,3-cycloaddition to form aromatic aldehyde-derivatized glycopeptides which were enriched by reversible hydrazone formation with hydrazide resins. Subsequently, glycopeptides could be eluted using hydroxylamine (Nishikaze et al., 2013).

In addition to capturing O-GlcNAcylated proteins, this strategy can be applied in live cell imaging, histological detection and modification stoichiometry quantification. Clark et al. labeled O-GlcNAcylated proteins selectively with a fluorescent reporter group to detect and image cellular O-GlcNAcylated proteins in living cells. (Clark et al., 2008). The Wu group applied this strategy to label histological specimens and demonstrated the change of O-GlcNAc levels during tumor development (Aguilar et al., 2017). To quantify O-GlcNAc stoichiometries on specific proteins, the Hsieh-Wilson group conjugated O-GlcNAcylated proteins with PEG mass tags. Compared to the nonglycosylated proteins, O-GlcNAcylated proteins showed the mass-shifted bands detected by immunoblotting with indicated antibodies. The occupancy levels of O-GlcNAc were determined by the intensity ratio of the glycosylated and nonglycosylated bands (Rexach et al., 2010). The Pratt group employed a semisynthetic O-GlcNAcylated protein standard combined with Strain-Promoted Cycloaddition (SPAAC) chemoenzymatic mass tagging protocol to improve the accuracy of O-GlcNAc stoichiometries analysis (Darabedian et al., 2018).

In summary, the biochemical tools and methods such as antibodies, lectins, metabolic, or chemoenzymatic labeling have different specificity and sensitivity in terms of enrichment and detection of O-GlcNAcylated proteins (Table 1). These strategies exhibit a broad range of applications including immunoblotting, proteomics, cellular and histological imaging (Table 1).
Mapping O-GlcNAcylation sites is vital for elucidating the functional role of O-GlcNAcylation in specific biological environment. However, this can be very challenging because there is no known consensus sequence of O-GlcNAcylation on proteins, and that O-GlcNAc occurs in substoichiometry on many proteins. In addition, the O-glycosidic bond is labile, easily lost in collision-induced dissociation (CID) mass spectrometry (Greis et al., 1996; Whelan and Hart, 2006). To address these challenges, Hart and his colleagues developed the BEMAD method (\(\beta\)-elimination followed by Michael addition with dithiothreitol), which chemically converts O-GlcNAcylated serine and threonine residues into stable thiol derivatives (Figure 5) (Wells et al., 2002). Using the isotope-labeled dithiothreitol, BEMAD had been applied to quantify and map O-GlcNAcylation sites after chemoenzymatic labeling (Zachara et al., 2011; Tsumoto et al., 2017). The replacement of labile glycosylation with a more stable dithiothreitol modification significantly improved the efficiency of site-identification (Wells et al., 2002). The Hart group further employed isobaric tags for relative and absolute quantification (iTRAQ) and BEMAD coupled with the chemoenzymatic labeling to compare the site-specific O-GlcNAc occupancy on proteins obtained from normal and diabetic erythrocytes, highlighting the differentially regulated O-GlcNAcylation in diabetic erythrocytes (Wang et al., 2009). Sakabe et al. used the chemoenzymatic labeling and BEMAD method to identify various O-GlcNAc sites on histones H2A, H2B, and H4, elucidating that dynamic O-GlcNAcylation is a critical part of the histone code (Sakabe et al., 2009). Moreover, Lund et al. employed a similar strategy to detect O-GlcNAc dynamics in response to T cell activation. More than 200 O-GlcNAcylated proteins were identified, among which are a number of proteins functionally related to RNA metabolism in human T cells, implying the functional importance of O-GlcNAcylation in T cell biology (Lund et al., 2016).

QUIC and TMT Tag Strategies for Profiling O-GlcNAcylation

Another approach couples O-GlcNAcylated peptide labeling/enrichment methods with tandem mass tagging for quantitative profiling of O-GlcNAcylation. The Hsieh-Wilson group developed a quantitative isotopic and chemoenzymatic tag (QUIC-Tag) strategy to identify and quantify O-GlcNAcylation in mouse brains in response to cellular stimulation. O-GlcNAcylated proteins were labeled selectively with a ketone-containing galactose analog via the chemoenzymatic strategy. The ketone functionality was reacted with an aminooxy biotin derivative, which can be captured by avidin chromatography. Subsequently, the proteins were digested and labeled with formaldehyde/NaCNBH3 or deuterated formaldehyde/NaCNBD3 by a modified dimethyl labeling strategy (Figure 6A). Coupled with tandem mass spectrometry, they demonstrated the dynamic O-GlcNAcylation...
in mediating neuronal communication (Khidekel et al., 2007). The tandem mass tag (TMT) probes containing an amine-reactive NHS-ester group, a spacer arm and an MS/MS reporter, are commonly used to label two to six peptide samples and measure relative protein expression levels with MS/MS (Thompson et al., 2003). Wang et al. integrated isobaric TMT labeling with chemoenzymatic enrichment to quantify O-GlcNAcylation between Alzheimer’s diseased brain and normal brain tissues. They identified 530 O-GlcNAcylated proteins covering 1,094 O-GlcNAcylation sites in the brain. The O-GlcNAcylation levels of 81 proteins in the Alzheimer’s patient’s brain were changed, indicating that dysregulation of O-GlcNAcylation may play an important role in the development of Alzheimer’s disease (Wang et al., 2017).

IsoTaG-Based Quantitative Proteomics

Recently, an approach termed Isotope Targeted Glycoproteomics (IsoTaG) was developed by the Bertozzi group to enrich labeled glycopeptides and confidently profile the intact glycoproteome by MS (Woo et al., 2015). Specifically, glycoproteins were labeled metabolically with the azido functionality. Then, the soTaG silane Probe 1, composed of an acid-cleavable biotin reagent containing an isotopic label and a terminal alkyne, was conjugated with the labeled glycoproteins. After capturing by streptavidin-agarose beads, the bound glycopeptides were released from the biotin tag and further sequenced by MS (Figure 7B). The quantification of the glycopeptides was achieved by using the pattern-searching algorithm mediated MS analysis to isotopically recoded species. IsoTaG shows a high sensitivity and repeatability when applied to low-abundance glycopeptides. Another strength of this method is that it promotes mass-independent targeted database searching for high-confidence distribution. With this strategy, Woo et al. metabolically labeled O-GlcNAcylated proteins with Ac4GalNAz to explore O-GlcNAcylation alterations in response to T-cell activation. They found that more than 500 glycopeptides underwent significant changes during T cell activation, facilitating the functional understanding of O-GlcNAcylation in resting and activated primary human T cells (Woo et al., 2018). Inspired by the IsoTaG strategy, Qin et al. developed an acid-cleavable dialkoxydiphenylsilane (DADPS) linker (Probe 2) to quantify O-GlcNAcylation. The isotopically labeled DADPS probe could be used to capture glycopeptides, which were then released after cleavage with mild acid and quantified by comparing the isotopic ratios using ETD-based tandem mass spectroscopy (Qin K. et al., 2018). Similarly, Li et al. designed an isotope-coded photocleavable probe for quantifying O-GlcNAcylation. O-GlcNAcylated proteins from two different cell states were chemoenzymatically captured by the Probe 3. The linker was cleaved when exposed to ultraviolet light (365 nm). The released glycopeptides were further analyzed for sites mapping and relative quantification (Li et al., 2019). They found that compared with sorafenib-sensitive liver carcinoma cells, 55 glycopeptides in the sorafenib-resistant cells showed an increase in O-GlcNAcylation stoichiometry, suggesting a role of O-GlcNAcylation in regulating tumor chemoresistance. Taken together, IsoTaG-based quantitative O-GlcNAcylation proteomics strategy greatly facilitates the quantification of glycoproteins by installing isotopic tags directly onto the O-GlcNAc moiety. The isotopic labeling can be used as the dual function to improve the reliability of glycopeptide assignment.
**SUMMARY AND OUTLOOK**

O-GlcNAcylation of intracellular proteins plays a fundamental role in health and disease. Effective ways to characterize the existence and dynamics of this modification will greatly promote the study of its functional significance. However, traditional methods, such as tritium labeling and the use of pan-O-GlcNAc antibodies, lack sensitivity and specificity. In addition, it is difficult to apply these methods to detect the changes and stoichiometry of O-GlcNAcylation in a complex system. The recent development of various chemical tools has provided exciting solutions to these problems. As stated above, a number of metabolic probes have been applied to detect and enrich O-GlcNAcylated proteins in living cells. A complementary chemoenzymatic labeling approach is also widely used to detect and profile O-GlcNAcylated proteins from cell lysates and tissues. Beyond the enrichment strategies, improvements in mass spectrometry technology have enabled quantifying and mapping O-GlcNAc sites with unprecedented accuracy.

O-GlcNAcylation is highly dynamic in response to nutrient availability and various environmental cues. With the variety of tools available to researchers, it is logical to profile and quantify O-GlcNAcylation under specific physiological contexts to reveal context-dependent functions of O-GlcNAc. In addition, current ways to modulate cellular O-GlcNAcylation rely on the use of small-molecule inhibitors or genetic knockdown/knockout, which lack the spatiotemporal resolution. Strategies that confer spatiotemporal control of O-GlcNAcylation are much needed. Moreover, O-GlcNAcylation on specific proteins has been shown to govern the protein function. Although there are some advances in developing strategies to manipulate protein-specific O-GlcNAcylation in cells (Gorelik and van Aalten, 2020; Ramirez et al., 2020; Ge et al., 2021), such studies are still in the infancy. In addition, the quantitative proteomics technique can’t necessarily distinguish between changes in O-GlcNAc stoichiometry vs. changes in protein expression, which remains to be addressed. Nevertheless, we anticipate that further development of chemical tools will provide an important foundation for uncovering the functional importance of O-GlcNAcylation in the frontiers of biology and human health.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
REFERENCES

Aguilar, A. L., Hou, X., Wen, L., Wang, P. G., and Wu, P. (2017). A Chemoenzymatic Histology Method for O-GlcNAc Detection. *Chem biochem* 18, 2416–2421. doi:10.1002/cbic.201700515

Alfaro, J. F., Gong, C.-X., Monroe, M. E., Aldrich, J. T., Claus, T. R. W., Purvine, S. O., et al. (2012). Tandem Mass Spectrometry Identifies many Mouse Brain O-GlcNAcylated Proteins Including EGF Domain-specific O-GlcNAc Transferases. *Proc. Natl. Acad. Sci.* 109, 7280–7285. doi:10.1073/pnas.1200425109

Best, M. D. (2009). Click Chemistry and Bioorthogonal Reactions: Unprecedented Selectivity in the Labeling of Biological Molecules. *Biochemistry* 48, 6571–6584. doi:10.1021/bi9017726

Bond, M. R., and Hanover, J. A. (2015). A Little Sugar Goes a Long Way: The Cell Biology of O-GlcNAc. *J. Cell Biol.* 208, 869–880. doi:10.1083/jcb.201510110

Boye, M., Carrico, I. S., Ganguli, A. S., Yu, S.-H., Hangauer, M. J., Hubbard, S. C., et al. (2011). Metabolic Cross-Link Allows Labeling of O-Linked -N-Acetylgalactosamine-Modified Proteins via the N-Acetylglactosamine Salvage Pathway. *Proc. Natl. Acad. Sci.* 108, 3141–3146. doi:10.1073/pnas.1010045108

Cecioni, S., and Vocadlo, D. J. (2013). Tools for Probing and Perturbing O-GlcNAc in Cells and *In Vivo*. *Curr. Opin. Chem. Biol.* 17, 719–728. doi:10.1016/j.cob.2013.06.030

Chalkley, R. J., Thalhammer, A., Schoepfer, R., and Burlingame, A. L. (2009). Characterization of a Mouse Monoclonal Antibody Specific for O-GlcNAc Modiﬁcation of RACK1 Promotes Hepatocellular Carcinogenesis. *J. Biol. Chem.* 284, 1691–1701. doi:10.1074/jbc.M010420200

Chen, J., Dong, X., Cheng, X., Zhu, Q., Zhang, J., Li, Q., et al. (2021). Ogt Controls Dissociation Mass Spectrometry on Native Peptides. *Mol. Cell Proteomics* 20, 6899–6905. doi:10.1073/pnas.2020691109

Chen, X., Wei, S. J., Yi, G., Xiong, X., and Yang, F. (2015). Quantitative Proteomics Using SILAC: Principles, Applications, and Developments. *Proteomics* 15, 3175–3192. doi:10.1002/pmic.201500108

Chuh, K. N., Batt, A. R., and Pratt, M. R. (2016). Chemical Methods for Encoding and Decoding of Posttranslational Modifications. *Cell Chem. Biol.* 23, 86–107. doi:10.1016/j.chembiol.2015.11.006

Chuh, K. N., and Pratt, M. R. (2015). Chemical Methods for the Proteome-wide Identification of Posttranslational Modified Proteins. *Curr. Opin. Chem. Biol.* 24, 27–37. doi:10.1016/j.cbpa.2014.10.020

Chuh, K. N., Zaro, B. W., Piller, F., Piller, V., and Pratt, M. R. (2014). Changes in Metabolic Chemical Reporter Structure Yield a Selective Probe of O-GlcNAc Modification. *J. Am. Chem. Soc.* 136, 12283–12293. doi:10.1021/ja504063c

Chuniewski-Bernard, C., Bastide, B., Lefebvre, T., Lemoine, J., Mounier, Y., and Michalski, J.-C. (2004). Identification of O-Linked N-Acetylgalactosamine Proteins in Rat Skeletal Muscle Using Two-Dimensional Gel Electrophoresis and Mass Spectrometry. *Mol. Proteomics* 3, 577–585. doi:10.1074/mcp.M400024-MCP200

Cieniewski-Bernard, C., Dupont, E., Deracinois, B., Lambert, M., and Bastide, B. (2014). Multiplexed Detection of O-GlcNAc–Modiﬁed Proteins Using Click Chemistry and Mass Spectrometry. *J. Proteome Res.* 13, 927–936. doi:10.1021/pr5003967

Haltiwanger, R. S., Holt, G. D., and Hart, G. W. (1990). Enzymatic Addition of O-GlcNAc to Nuclear and Cytoplasmic Proteins. *J. Biol. Chem.* 265, 2563–2568. doi:10.1016/S0021-9258(19)39838-2

Hao, Y., Fan, X., Shi, Y., Zhang, C., Sun, D.-e., Qin, K., et al. (2019). Next-generation Unnatural Monosaccharides Reveal that ESRRB-O-GlcNAcylation Regulates Pluripotency of Mouse Embryonic Stem Cells. *Nat. Commun.* 10, 4065. doi:10.1038/s41467-019-11942-y

Hart, G. W., Slawson, C., Ramirez-Corrales, G., and Lagerlof, O. (2011). Cross Talk between O-GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription, and Chronic Disease. *Annu. Rev. Biochem.* 80, 825–858. doi:10.1146/annurev-biochem-060608-102511

Hayes, B. K., Greis, K. D., and Hart, G. W. (1995). Specific Isolation of O-Linked N-Acetylgalactosamine Glycopeptides from Complex Mixtures. *Anal. Chem.* 68, 119–122. doi:10.1021/ac9406685

Jang, H., Kim, T. W., Yoon, S., Choi, S.-Y., Kang, T.-W., Kim, S.-Y., et al. (2012). O-GlcNAc Regulates Pluripotency and Reprogramming by Directly Acting on Core Components of the Pluripotency Network. *Cell Stem cell* 11, 62–74. doi:10.1016/j.stem.2012.03.001

Khidekel, N., Arndt, S., Lamarre-Vincent, N., Lippert, A., Poulin-Kerstien, K. G., Ramakrishnan, B., et al. (2003). A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications. *J. Am. Chem. Soc.* 125, 16162–16163. doi:10.1021/ja035845r

Khidekel, N., Ficarro, S. B., Clark, P. M., Bryan, M. C., Swaney, D. L., Rexach, J. E., et al. (2007). Probing the Dynamics of O-GlcNAc Glycosylation in the Brain Using Quantitative Proteomics. *Nat. Chem. Biol.* 3, 339–348. doi:10.1038/nchembio881

Khidekel, N., Ficarro, S. B., Peters, E. C., and Hsieh-Wilson, L. C. (2004). Exploring the O-GlcNAc Proteome: Direct Identification of O-GlcNAc-Modified Proteins from the Brain. *Proc. Natl. Acad. Sci.* 101, 13132–13137. doi:10.1073/pnas.0403471101

Kochibe, N., and Matta, K. L. (1989). Purification and Properties of an N-acetylglucosamin-specific Lectin from Psathyrella Velutina Mushroom. *J. Biol. Chem.* 264, 173–177. doi:10.1002/1955-8129(173)31239-5

Lefebvre, T., Baert, F. d. r., Bodart, J.-F. o., Flament, S. p., Michalski, J.-C., and Vilain, J. P. (2004). Modulation of O-GlcNAc Glycosylation duringXenopus Oocyte Maturation. *J. Cell Chem. Biol.* 93, 999–1010. doi:10.1002/jcb.20242

Li, J., Li, Z., Duan, X., Qin, K., Deng, L., Sun, S., et al. (2019). An Isotope-Coded Photocleavable Probe for Quantitative Profiling of Protein O-GlcNAcylation. *ACS Chem. Biol.* 14, 4–10. doi:10.1021/acschembio.8b01052

Li, J., Wang, J., Wen, L., Zhu, H., Li, S., Huang, K., et al. (2016). An OGA-Resistant Probe Allows Specific Visualization and Accurate Identification of O-GlcNAc-Modified Proteins in Cells. *ACS Chem. Biol.* 11, 3002–3006. doi:10.1021/acschembio.6b00678
Wang, Z., Udeshi, N. D., O’Malley, M., Shabanowitz, J., Hunt, D. F., and Hart, G. W. (2010a). Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry. Mol. Cell Proteomics 9, 153–160. doi:10.1074/mcp.M900268-MCP200

Wang, Z., Udeshi, N. D., Slawson, C., Compton, P. D., Sakabe, K., Cheung, W. D., et al. (2010b). Extensive Crosstalk between O-GlcNAcylation and Phosphorylation Regulates Cytokinesis. Sci. Signalig 3, ra2. doi:10.1126/scisignal.2000526

Wells, L., Vosseller, K., Cole, R. N., Cronshaw, J. M., Matunis, M. J., and Hart, G. W. (2002). Mapping Sites of O-GlcNAc Modification Using Affinity Tags for Serine and Threonine post-translational Modifications. Mol. Cell Proteomics 1, 791–804. doi:10.1074/mcp.m200048-mcp200

Whelan, S. A., and Hart, G. W. (2006). Identification of O-GlcNAc Sites on Proteins. Methods Enzymol. 415, 113–133. doi:10.1016/S0076-6879(06)15008-9

Woo, C. M., Iavarone, A. T., Spiciarich, D. R., Palaniappan, K. K., and Bertozzi, C. R. (2015). Isotope-targeted Glycoproteomics (IsoTaG): a Mass-independent Platform for Intact N- and O-Glycopeptide Discovery and Analysis. Nat. Methods 12, 561–567. doi:10.1038/nmeth.3366

Woo, C. M., Lund, P. J., Huang, A. C., Davis, M. M., Bertozzi, C. R., and Pitteri, S. J. (2018). Mapping and Quantification of over 2000 O-Linked Glycopeptides in Activated Human T Cells with Isotope-Targeted Glycopeptidomics (IsoTag). Mol. Cell Proteomics 17, 764–775. doi:10.1074/mcp.RA117.000261

Yoshida, N., Mortara, R. A., Araguth, M. F., Gonzalez, J. C., and Russo, M. (1989). Metacyclic Neutralizing Effect of Monoclonal Antibody 10D8 Directed to the 35- and 50-kilodalton Surface Glycoconjugates of Trypanosoma Cruzi. Infect. Immun. 57, 1663–1667. doi:10.1128/IAI.57.6.1663-1667.1989

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zhu and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.